Expanded information on the latest progress within the epilepsy project CG01 and the company’s new lipodystrophy project
During the last weeks, CombiGene has taken several significant steps forward. The development can be summarized as follows: our epilepsy project CG01 took two important steps towards clinical studies when we made our definitive choice of CRO and CDMO partners, and we will finalize the projects pre-clinical phase with the biodistribution and toxicology studies that are planned for the second half of 2020.
Our project portfolio has increased by one additional project – the lipodystrophy project. And we have, with the acquisition of Panion Animal Health, now full control of all IP related to the CG01 project, which is important in negotiations with potential partners.
All in all, this means that we now have a broader and even more interesting project portfolio, that the road towards clinical studies for CG01 is staked out, and that we are better equipped in our discussions with future partners.
Based on the above, we have updated our web site with new and expanded information on CombiGene’s projects. We encourage everybody to visit it. And – please tell your friends and family about CombiGene and gene therapy. We want as many as possible to join us on the exciting research journey that lies ahead.